Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

128 results about "SIGLEC" patented technology

Siglecs (Sialic acid-binding immunoglobulin-type lectins) are cell surface proteins that bind sialic acid. They are found primarily on the surface of immune cells and are a subset of the I-type lectins. There are 14 different mammalian Siglecs, providing an array of different functions based on cell surface receptor-ligand interactions.

Enhanced regulatory t cells and methods of use thereof

Methods and compositions for treating fibrosis (e.g., cardiac fibrosis), or other conditions associated with inflammation and / or fibrosis are provided. Methods can include administering a nucleic acid encoding a sialic acid-binding immunoglobulin-type lectin 9 (Siglec-9) protein to a subject in need of fibrosis treatment, where the Siglec-9 protein is expressed by the nucleic acid in regulatory T (Treg) cells in the subject. Methods and compositions can include Treg cells that overexpress Siglec-9 to enhance the ability of Treg cells to target cells expressing amine oxidase, copper containing 3 (AOC3), including fibroblasts or myofibroblasts. In some embodiments, the enhanced Treg cells are targeted to myofibroblasts (e.g., cardiac myofibroblasts) with elevated expression of fibrotic genes.
Owner:CEDARS SINAI MEDICAL CENT

PD-L1 and Siglec-15 enriched engineered small extracellular vesicle hydrogel as well as preparation method and application thereof

The invention relates to the technical field of biomedical materials, in particular to engineered small extracellular vesicle hydrogel enriched with PD-L1 and Siglec-15 as well as a preparation method and application of the engineered small extracellular vesicle hydrogel. The engineering small extracellular vesicle hydrogel is enriched with PD-L1 and Siglec-15 at the same time, the engineering small extracellular vesicle hydrogel comprises a hydrogel base body and PDL1-Siglec15-sEVs loaded in the hydrogel base body, and the PDL1-Siglec15-sEVs are small extracellular vesicles with the PD-L1 and the Siglec-15 in an overexpression mode. Compared with natural small extracellular vesicles and a traditional wound surface treatment strategy, the engineered small extracellular vesicle hydrogel has the advantages that PD-L1 and Siglec-15 can be enriched in the vesicles, so that more accurate immune microenvironment regulation and control can be realized on the local part of a wound surface, excessive inflammatory response is moderately inhibited, phenotype transformation of macrophages to be beneficial to tissue regeneration is promoted, and the wound surface treatment effect is improved. The hydrogel is used as a carrier and can provide a moist healing environment and a three-dimensional scaffold structure, so that the residence time of the engineered small extracellular vesicles on the local wound surface is remarkably prolonged, and slow release is realized.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL

Compositions and methods for multiplex base editing in hematopoietic cells

When a cancer patient is administered an anti-cancer therapy targeting a lineage specific cell-surface antigen (e.g., CD33 (Siglec-3), CLL-1, CD123, CD327 (Siglec-6), and / or CD312 (EMR2)), e.g., in the form of an immunotherapeutic agent, the therapy can deplete not only cancer cells expressing the lineage-specific cell-surface antigen, but also noncancerous cells expressing the lineage-specific cell-surface antigen in an “on-target, off tumor” effect. This disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in an endogenous lineage-specific cell-surface antigen (e.g., CD33 (Siglec-3), CLL-1, CD123, CD327 (Siglec-6), and / or CD312 (EMR2)) gene. The disclosure also provides compositions, e.g., gRNAs, that can be used to make such a modification.
Owner:SYZYGYMED INC

Antibodies targeting c-Kit and / or siglecc and uses thereof

Undesirable mast cell activity is associated with various diseases or conditions, such as allergy, inflammatory diseases, autoimmune diseases, and cancer. New and improved therapeutic agents that can target c-Kit and / or siglec-6 (e.g., for mast cell related diseases or disorders) still have been desired. Disclosed herein are molecules, such as antibodies and antibody fragments, capable of binding to c-Kit and / or siglec-6. Disclosed herein are molecules, such as antibodies and antibody fragments, capable of binding to c-Kit and / or siglec-6.
Owner:SANTA ANA BIO INC

Anti-VSIG4 and Anti-siglec-7 inhibitory antibody against intermolecular interaction between VSIG4 and siglec-7

To create an antibody that inhibits an immune checkpoint function based on interaction between VSIG4 and Siglec-7 and exhibits antitumor activity, and to provide an anti-tumor immune response activator which includes the antibody as an active ingredient.SOLUTION: The present invention provides an anti-tumor immune response activator including an antibody that inhibits intermolecular interaction between VSIG4 and Siglec-7 or a functional fragment thereof.SELECTED DRAWING: Figure 9
Owner:THE UNIV OF TOKYO

Anti-siglec-6 antibodies and methods of use thereof

PCT designated stage expiredWO2025005961A1AntipyreticAnalgesicsMast cellAntiendomysial antibodies
The present disclosure provides anti-Siglec-6 antibodies and their use in treating and preventing mast cell-mediated disorders, as well as compositions and kits comprising the anti- Siglec-6 antibodies.
Owner:ALLAKOS INC

Novel Immune Cell Engagers For Immunotherapy

PendingUS20240409649A1Antibacterial agentsAntibody ingredientsDiseaseActivated Natural Killer Cell
The present invention provides natural killer engagers specific for activating natural killer cells through binding to a Siglec, and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.
Owner:THE WISTAR INST OF ANATOMY & BIOLOGY

Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use

Multi-specific binding proteins that bind to and kill human cancer cells expressing CD33 (Siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of CD33 expressing cancer. The invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33 and exhibit high potency and maximum lysis of target cells compared to anti-CD33 monoclonal antibodies. The multi-specific binding proteins comprise a CD33-binding domain, an NKG2D-binding domain and a CD16-binding domain.
Owner:DRAGONFLY THERAPEUTICS INC

Siglec-6 antibodies, derivative compounds and related uses

The invention provides antibodies, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as derivative molecules such as bispecific T-cell engagers, antibody-drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize Siglec-6 and related compositions. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Anti-siglec-15 antibodies and uses thereof

The present invention provides anti-Siglec-15 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-15 antibodies and fragments thereof.
Owner:ADAPTAM THERAPEUTICS SL +3

Variant nucleic acid libraries for mast cells

Provided herein are antibodies and antibody fragments relating to SIGLEC-8 and CD117. Provided herein are methods and compositions relating to SIGLEC-8 and / or CD117 libraries having nucleic acids encoding for a scaffold comprising a SIGLEC-8 and / or CD117 domain. SIGLEC-8 and / or CD117 libraries described herein encode for immunoglobulins such as antibodies.
Owner:TWIST BIOSCIENCE CORP

Anti-siglec-7 antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and / or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Owner:ALECTOR LLC

Anti-siglec compositions and uses thereof for treating neurodegenerative diseases

Provided herein are anti-Siglec-10 and Siglec-8 antibody compositions and combinations thereof, and their use in the treatment of neurodegenerative diseases.
Owner:ONCOC4 INC

Application of Siglec-10 / G or fusion protein containing Siglec-10 / G protein structure in preparation of glioma treatment medicine

The invention discloses an application of Siglec-10 / G or a fusion protein containing a Siglec-10 / G protein structure in preparation of a medicine for treating glioma. The application finds that Siglec-10 / G is a new key myeloid immune checkpoint molecule in a glioma immunosuppression microenvironment, and reveals a specific molecular mechanism that Siglec-10 / G and related action signals (such as MUC1, CKB and GOT1) thereof influence glioma generation. The Rebinant Mouse Siglec-10 (C-Fc) provided by the invention can be combined with a ligand on the surface of a tumor cell, so that endogenous Siglec-10 / G signal transduction on MDM is competitively blocked, the anti-tumor immunity of a tumor-bearing mouse is improved, the growth of glioma is inhibited, the survival time of the tumor-bearing mouse is prolonged, and the Rebinant Mouse Siglec-10 (C-Fc) can be used for treating glioma.
Owner:NANJING MEDICAL UNIV +1

A polypeptide targeting siglec-15, pet molecular probe and preparation method and application thereof

The application relates to a polypeptide, a PET molecular probe and a preparation method and application of the polypeptide for targeting Siglec-15, wherein the polypeptide is any one of the following: (1) having an amino acid sequence DLDMHGS and / or DLNRHGS; (2) a derivative polypeptide formed by one or more amino acid substitutions, deletions, insertions or additions to the amino acid sequence shown in (1); and (3) a derivative polypeptide obtained by chemical or genetic modification of the polypeptide in (1) or (2). The modified polypeptide comprises the above-mentioned polypeptide for targeting Siglec-15 and a connecting group connected to the N end of the polypeptide for targeting Siglec-15. The PET molecular probe for targeting Siglec-15 comprises the modified polypeptide, a chelating agent and a radionuclide. The probe of the application has excellent stability and good water solubility, has high affinity and strong selectivity to Siglec-15, can sensitively reflect the expression level of Siglec-15 in tumors, and has a relatively fast in-vivo clearance rate and ideal imaging speed. In a Siglec-15 positive tumor model, the probe can be enriched in the lesion area in a short time after injection, and a PET image with good signal-to-noise ratio can be obtained.
Owner:JIANGSU INST OF NUCLEAR MEDICINE

Novel lipid nanoparticle compositions and uses thereof

The present invention provides a lipid nanoparticle (LNP) formulation comprising at least one sialic acid (SA)-containing lipid. The LNP formulation can effectively bind to cell surface Siglec, transfect specific cells in vitro, and target specific cells in vivo. The present invention also provides a method for using the LNP composition described herein for pharmaceutical applications. For example, the LNP provided herein is useful for intracellular delivery of nucleic acid therapeutic agents to a subject.
Owner:CYTODIGM INC

An engineered small extracellular vesicle hydrogel enriched with pd-l1 and siglec-15, and preparation method and application thereof

The present application relates to the technical field of biomedical materials, in particular to an engineered small extracellular vesicle hydrogel enriched with PD-L1 and Siglec-15, and a preparation method and application thereof. The engineered small extracellular vesicle hydrogel is simultaneously enriched with PD-L1 and Siglec-15, and comprises a hydrogel matrix and PDL1-Siglec15-sEVs loaded in the hydrogel matrix, wherein the PDL1-Siglec15-sEVs are small extracellular vesicles overexpressing PD-L1 and Siglec-15. Compared with natural small extracellular vesicles and traditional wound treatment strategies, the engineered small extracellular vesicle hydrogel of the present application can realize more precise immune microenvironment regulation at the local wound by enriching PD-L1 and Siglec-15 in the vesicles, moderately inhibit excessive inflammatory response, promote the phenotype transformation of macrophages to a phenotype conducive to tissue regeneration, help smooth transition from the inflammatory stage to the proliferation and reconstruction stage, and the hydrogel as a carrier can provide a moist healing environment and a three-dimensional scaffold structure, significantly prolong the residence time of the engineered small extracellular vesicles at the local wound, and realize slow release.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL

Siglec-15 affinity peptide and application thereof

The invention belongs to the technical field of biological pharmacy, and particularly discloses a Siglec-15 affinity peptide and application thereof. According to the invention, a phage display heptapeptide library high-throughput screening technology is adopted, Siglec-15 affinity peptide 7-8 is obtained through multiple rounds of screening, and the Siglec-15 affinity peptide 7-8 is optimized and modified to obtain a reversed sequence flip peptide d-7-8. Experimental results show that the Siglec-15 affinity peptide can be used for affinity of Siglec-15 protein and blocking the interaction between Siglec-15 and a ligand Sialyl-Tn of Siglec-15, so that the anti-tumor effect is achieved; an in-vitro cell level experiment shows that the Siglec-15 affinity peptide has a relieving effect on inhibition of Siglec-15 on CD8 + T cell proliferation, has an obvious immune activation effect, does not have obvious toxic or side effects, can be used for preparing an anti-tumor drug or a detection reagent taking Siglec-15 as a target spot, and has a relatively good medical application prospect.
Owner:ZHENGZHOU UNIV

Siglec ligands, conjugates, and methods of use thereof

PCT designated stage expiredWO2024259007A2Sugar derivativesPeptide/protein ingredientsAuto antigenCombinatorial chemistry
The present disclosure provides Siglec ligands that have particular linkers. Also provided are conjugates that include a biologically active substance that is covalently bonded to the connecting group of the Siglec ligands. For instance, the biologically active substance can be a biotherapeutic or an autoantigen. The linkers can have advantageous properties that improve the technical qualities of the corresponding conjugates.
Owner:OSPREY BIOPHARMACEUTICALS INC

Fusion proteins comprising extracellular domain of human CD22

A method for restoring immune control over autoimmunity in a subject in need thereof is described. The method comprises the step of administering to the subject a therapeutically effective amount of an antibody that disrupts Siglec-binding in cis. A method of screening for an antibody that is disruptive of Siglec binding in cis, a method of making an antibody for restoring immune control over autoimmunity to a subject in need, a method of modulating autoimmunity in an immune cell and a method of releasing sialic acid binding site of human CD22 from cis-binding configuration to trans-ligand formation in treating autoimmunity in a subject in need thereof are also described. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also disclosed herein.
Owner:SINOMAB BIOSCI

Anti-siglec-9 antibodies and uses thereof

The present invention provides anti-Siglec-9 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-9 antibodies and fragments thereof.
Owner:ADAPTAM THERAPEUTICS SL +1

Anti-SIGLEC-5 antibodies and methods of use thereof

The present disclosure generally relates to compositions comprising antibodies, such as monoclonal antibodies, chimeric antibodies, humanized antibodies, antibody fragments, etc., that specifically bind to Siglec-5 proteins, such as human Siglec-5, and the use of such compositions in the prevention, risk reduction or treatment of individuals in need thereof.
Owner:艾利妥

Anti-siglec-9 antibodies and uses thereof

The present invention provides anti-Siglec-9 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-9 antibodies and fragments thereof.
Owner:ADAPTAM THERAPEUTICS SL +1

Antibodies for siglec-15 and methods of use thereof to treat disuse osteoporosis

Provided herein are compositions that immunospecifically bind to Siglec-15, small molecules, peptides, or other entities that may bind Siglec-15 in a similar fashion. Methods of use are provided for Siglec-15 targeting therapeutics to restore bone homeostasis by inhibiting bone resorption and increase bone formation, specifically in non-ambulatory people or in people with disuse osteoporosis. The therapeutics referenced here may be used to overcome the need for mechanical loading on the bone to maintain high quality skeleton.
Owner:NEXTCURE INC

Dual-regulation medicine composition for treating sepsis as well as preparation method and application of dual-regulation medicine composition

The invention discloses a dual-regulation pharmaceutical composition for sepsis treatment, a preparation method and application, and belongs to the technical field of biological medicine, and the pharmaceutical composition comprises doxorubicin liposome, all-trans retinoic acid phospholipid complex nanoparticles and antibiotics. Preferably, the doxorubicin liposome is prepared from the sialic acid modified doxorubicin liposome, the sialic acid modified all-trans retinoic acid phospholipid compound nanoparticles and meropenem. Dynamic monitoring of myeloid-derived suppressor cells MDSCs and sialic acid binding immunoglobulin type lectin-E (SiglecE) positively expressed myeloid-derived suppressor cells, namely SiglecE + MDSCs cell subsets, in the middle and later periods of sepsis is used as an evaluation index of the immunosuppression state, and dual regulation and control of sepsis acute inflammation and immunosuppression are achieved. The method has remarkable advantages in the aspects of increasing the survival rate, precisely targeting immunosuppression, improving the drug delivery efficiency and the like, and a brand new solution is provided for clinical treatment of sepsis.
Owner:SHENYANG PHARMA UNIV

Nanobodies against sialoadhesin and related biomaterials and uses thereof

The application discloses a nanobody against sialic acid-binding immunoglobulin-like lectin 15 and a related biomaterial and application thereof, and belongs to the technical field of immunotherapy biological medicine. The nanobody against sialic acid-binding immunoglobulin-like lectin 15 or an antigen-binding fragment thereof provided by the application comprises three complementarity determining regions CDR1, CDR2 and CDR3, the nanobody is S1, the amino acid sequence of CDR1 of the S1 is SEQ ID No. 6, the amino acid sequence of CDR2 of the S1 is SEQ ID No. 7, and the amino acid sequence of CDR3 of the S1 is SEQ ID No. 8. The nanobody against sialic acid-binding immunoglobulin-like lectin 15 provided by the application can play a role in the development of a therapeutic drug for a cancer patient with high expression of Siglec-15.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Bispecific Natural Killer Engagers That Target Siglec-7

PendingUS20250223369A1Polypeptide with localisation/targeting motifPowder deliveryDiseaseActivated Natural Killer Cell
The present invention provides natural killer engagers specific for activating natural killer cells through binding to Siglec-7, and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.
Owner:THE WISTAR INST OF ANATOMY & BIOLOGY

Siglec ligands, conjugates, and methods of use thereof

Provided are siglec ligands and siglec conjugates. Also provided are methods of use of such conjugates, as well as pharmaceutical compositions thereof.
Owner:ADAXION THERAPEUTICS INC